BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 14752794)

  • 1. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience.
    Chi SN; Conklin LS; Qin J; Meyers PA; Huvos AG; Healey JH; Gorlick R
    Pediatr Blood Cancer; 2004 Jan; 42(1):46-51. PubMed ID: 14752794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients.
    Bacci G; Longhi A; Bertoni F; Briccoli A; Versari M; Pignotti E; Picci P
    Acta Orthop; 2006 Dec; 77(6):938-43. PubMed ID: 17260205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Perin S; Forni C; Fabbri N; Salduca N; Versari M; Smith KV
    Eur J Cancer; 2001 Jan; 37(1):32-8. PubMed ID: 11165127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.
    Bacci G; Briccoli A; Longhi A; Ferrari S; Mercuri M; Faggioli F; Versari M; Picci P
    Acta Oncol; 2005; 44(7):748-55. PubMed ID: 16227167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
    Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
    Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
    Machak GN; Polotskiĭ BE; Meluzova OM; Chernov IS; Aliev MD
    Vopr Onkol; 2010; 56(2):220-5. PubMed ID: 20552902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?
    Palmerini E; Torricelli E; Cascinu S; Pierini M; De Paolis M; Donati D; Cesari M; Longhi A; Abate M; Paioli A; Setola E; Ferrari S
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27792. PubMed ID: 31058424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.
    Chou AJ; Merola PR; Wexler LH; Gorlick RG; Vyas YM; Healey JH; LaQuaglia MP; Huvos AG; Meyers PA
    Cancer; 2005 Nov; 104(10):2214-21. PubMed ID: 16206297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
    Punanov IuA; Gafton GI; Gudz' IuV; Nabokov VV; Ivanova TV; Safonova SA; Levchenko EV; Kupatadze DD; Novik VI; Lazareva IuR; Krzhivitskiĭ PI; Petrov VG
    Vopr Onkol; 2012; 58(2):275-81. PubMed ID: 22774537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
    Bacci G; Ruggieri P; Picci P; Briccoli A; Ferraro A; Ferrari S; Tienghi A; Iantorno D; Campanacci M
    J Chemother; 1995 Jun; 7(3):230-9. PubMed ID: 7562020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative therapy for osteosarcoma.
    Errani C; Longhi A; Rossi G; Rimondi E; Biazzo A; Toscano A; Alì N; Ruggieri P; Alberghini M; Picci P; Bacci G; Mercuri M
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):217-27. PubMed ID: 21342041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
    J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
    Hawkins DS; Arndt CA
    Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma.
    Aung L; Gorlick R; Healey JH; Shi W; Thaler HT; Shorter NA; Huvos AG; Meyers PA
    J Clin Oncol; 2003 Jan; 21(2):342-8. PubMed ID: 12525528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
    Bacci G; Balladelli A; Palmerini E; Alberghini M; Pollastri P; Galletti S; Mercuri M; Picci P
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):908-12. PubMed ID: 19131777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
    Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F
    Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.